DOI:
10.1055/s-00000031
Klinische Monatsblätter für Augenheilkunde
LinksClose Window
References
Pearce I, Banerjee S, Burton BJ. et al.
Ranibizumab 0.5 mg for diabetic macular edema with bimonthly monitoring after a phase of initial treatment: 18-month, multicenter, phase IIIB RELIGHT study.
Ophthalmology 2015;
122: 1811-1819
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.